Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
/0 Comments/in Uncategorized/by CURCNeal D. Shore, MD, Lead Investigator for the CREST trial.
Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is Now
/0 Comments/in Uncategorized/by CURCAuthors: Neal Shore, MD , Sarah M. Nielsen, MS , Edward D. Esplin, MD, PhD, Emmanuel S. Antonarakis, MD, Pedro C. Barata, MD, Tomasz M. Beer, MD, Himisha Beltran, MD, Alan Bryce, MD, Michael S. Cookson, MD, E. David Crawford, MD, Tanya B. Dorff, MD, Daniel J. George, MD, Elisabeth I. Heath, MD, Brian T. Helfand, MD, PhD, Maha Hussain, MD, Rana R. Mckay, MD, Alicia K. Morgans, MD, MPH, Michael J. Morris, MD, Channing J. Paller, MD, Ashley E. Ross, MD, PhD, Oliver Sartor, MD, John Shen, MD, Paul Sieber, MD, Matthew R. Smith, MD, PhD, David R. Wise, MD, PhD, Andrew J. Armstrong, MD
In the Era of Treatment Intensification for Prostate Cancer, Why Are Some Living in the Past?
/0 Comments/in Uncategorized/by CURCEditorial Comment: Integrating Broad Panel Somatic and Germline Testing in Prostate Cancer Care
/0 Comments/in Uncategorized/by CURCAuthor Neal Shore, MD, FACS, Carolina Urologic Research Center, AUC Urology Specialists, 823 82nd Parkway, Myrtle Beach, SC , 29572
Evaluating the Importance of Practice-level Factors on Adherence to Prostate Cancer Treatment Guidelines in Urology
/0 Comments/in Uncategorized/by CURCAuthors: Neal Shore ∙ Gordon Brown ∙ Benjamin Lowentritt ∙ Lorraine O’Donnell ∙ Wanda Wilt ∙ Sabree Burbage ∙ Ibrahim Khilfeh ∙ Franklin Gaylis
Testosterone recovery post discontinuation of androgen deprivation for the treatment of advanced prostate cancer
/0 Comments/in Uncategorized/by CURCNeal D Shore* , Alicia K Morgansb and Ronald F Tutrone
The landscape of androgen deprivation therapies for the treatment of advanced prostate cancer
/0 Comments/in Uncategorized/by CURCAuthors Neal D Shore* , Michael S Cooksonb and Eleni Efstathiou
Enzalutamide in Men With High-Risk Biochemically Recurrent Prostate Cancer: Rationale and Treatment Considerations From EMBARK
/0 Comments/in Uncategorized/by CURCAuthors Neal D. Shore, Ugo De Giorgi, and Stephen J. Freedland
Treatment intensification with radium-223 plus enzalutamide in patients with metastatic castration-resistant prostate cancer
/0 Comments/in Uncategorized/by CURCContact
Carolina Urologic Research Center
823 82nd Parkway, Suite B
Myrtle Beach, SC 29572
Phone: (843) 839-1679
Fax: (843) 286-0119
Email:
info@curcmb.com
Recent Happenings
- Development of TAR-200: A novel targeted releasing system designed to provide sustained delivery of gemcitabine for patients with bladder cancer
- Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
- Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is Now
- In the Era of Treatment Intensification for Prostate Cancer, Why Are Some Living in the Past?